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Background: Alcohol, tobacco, illicit drugs, and psychoactive pharmaceuticals’ use is 
associated with a higher likelihood of developing several diseases and injuries and, as a 
consequence, considerable health-care expenditures. There is yet a lack of consistent 
methodologies to estimate the economic impact of addictive substances to society. 
The aim was to assess the methodological approaches applied in social cost studies 
estimating the economic impact of alcohol, tobacco, illicit drugs, and psychoactive 
pharmaceuticals.
Methods: A systematic literature review through the electronic databases, Medline 
(PubMed) and Web of Science, was performed. Studies in English published from 1997 
examining the social costs of the addictive substances alcohol, tobacco, illicit drugs, and 
psychoactive pharmaceuticals were eligible for inclusion.
Results: Twelve social cost studies met the inclusion criteria. In all studies, the direct 
and indirect costs were measured, but the intangible costs were seldom taken into 
account. A wide variety in cost items included across studies was observed. Sensitivity 
analyses to address the uncertainty around certain cost estimates were conducted in 
eight studies considered in the review.
Conclusion: Differences in cost items included in cost-of-illness studies limit the com-
parison across studies. It is clear that it is difficult to deal with all consequences of 
substance use in cost-of-illness studies. Future social cost studies should be based on 
sound methodological principles in order to result in more reliable cost estimates of the 
economic burden of substance use.
Keywords: cost-of-illness, methodology, review, alcohol, tobacco, illicit drugs, psychoactive pharmaceuticals
iNTRODUCTiON
The use and/or misuse of the addictive substances alcohol, tobacco, and illicit drugs are a worldwide 
problem contributing to the global burden of disease (1). Alcohol is responsible for 3.3 million deaths 
(5.9% of all deaths worldwide) each year and accounts for 5.1% of the global burden of disease (2). In 
2015, tobacco smoking including second-hand smoking accounted for 7.2 million deaths (1), while 
for illicit drugs, this was 0.8% (3). In addition, the misuse of psychoactive pharmaceuticals such 
FigURe 1 | Systematic literature review search process.
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as antidepressants, sedatives, anxiolytics, and antipsychotics has 
also become a public health concern (4). The scale of the impact of 
the misuse of such pharmaceuticals worldwide remains, however, 
unknown due to a lack of epidemiological data. Nevertheless, a 
high prevalence of non-medical prescription drug use has been 
reported in countries such as the US, Canada, Australia, and 
some European countries (5, 6).
The use of alcohol, tobacco, illicit drugs, and psychoactive 
pharmaceuticals is associated with a considerable risk of develop-
ing a number of diseases and injuries (7, 8). So, it is clear that they 
affect the health and economic welfare of societies. The economic 
burden of these addictive substances can be estimated by cost-
of-illness studies (9). In such studies, the social costs associated 
with a particular disease or condition are measured by estimating 
the direct, the indirect, and the intangible costs. The direct costs 
are those to deal with the disease, or condition, or its proximate 
effects (e.g., hospitalization and medication). The indirect costs 
are the costs related to lost human productivity (e.g., productivity 
losses due to morbidity or mortality). The intangible costs can 
be considered as non-financial welfare losses such as reduced 
health-related quality of life (9, 10).
In general, two approaches are used in cost-of-illness stud-
ies, namely, the prevalence-based and the incidence-based 
approaches. Prevalence-based studies estimate the costs associ-
ated with past and current consequences of the disease or condi-
tion in a given time period, typically a year. The incidence-based 
approach estimates the costs and consequences associated with 
new cases of the disease or condition in the current and future 
years (8). The indirect costs can be measured using the human 
capital method, the demographic method, and the friction cost 
method. The human capital method measures the current and 
future productivity losses occurring in the current year (10, 11). 
The demographic method measures the current costs from all 
current and past productivity losses by comparing the current 
population with a hypothetical population in which the disease 
or condition did not exist (10, 11). The friction cost method takes 
into account the productivity losses related to the time period 
until another employee takes over the work at the same capacity 
(12). The epidemiological concept of substance-attributable frac-
tions (SAF) can be used to quantify the proportion of morbidity 
and mortality of diseases and conditions known to be causally 
related to substance use (13, 14).
Comparing the findings of social cost studies is difficult and 
must be cautiously interpreted due to differences in method-
ologies such as cost items included or calculation methods (15). 
Social cost studies are frequently characterized by some degree 
of uncertainty related to the availability and reliability of data 
sources (10). With the current review, it was the aim to evaluate 
the methodological approaches applied in social cost studies 
of the addictive substances alcohol, tobacco, illicit drugs, and 
psychoactive pharmaceuticals.
MeTHODS
A systematic literature search was conducted searching the 
electronic peer-reviewed databases, Medline (PubMed) and 
Web of Science. For each of the databases, a search algorithm 
was developed adapted to the specific requirements or features 
of the databases using the following entry terms: “cost-of-illness” 
(MeSH), “health-care costs” (MeSH), “cost,” “costs,” “social,” 
“societal,” “direct,” “indirect,” “intangible,” “alcohol,” “tobacco” 
(MeSH), “illicit,” “illegal,” and “psychotropic drugs” (MeSH). The 
initial search yielded 1,173 records. After excluding the duplicates 
(n = 15), 1,158 records remained for further evaluation (Figure 1). 
First, a selection on title and/or abstract was performed. Studies in 
English conducted in high-income Western countries estimating 
the social costs of the substances alcohol, tobacco, illicit drugs, 
and psychoactive pharmaceuticals were eligible for inclusion. In 
1996, the first edition of the guidelines for estimating the costs of 
substance abuse was published (16). Therefore, for this review, 
studies published from January 1997 until December 2015 were 
considered. Studies were excluded if they consisted of health 
economic evaluations of substance abuse treatment or prevention 
programs, or if the geography, language, and time period criteria 
were different from those described under the inclusion criteria. 
The selection on title and/or abstract resulted in 19 records of 
which the full text was evaluated in detail on the inclusion and 
exclusion criteria. Seven records were excluded resulting in 12 
social cost studies included in the review. The outcomes of inter-
est included the substance under study, the cost measurement 
approach (incidence-based or prevalence-based), the major cost 
categories considered (direct, indirect, and intangible costs), 
TABLe 1 | Overview of social cost studies included in the literature review.
Reference Country Substance Cost categories Cost measurement Productivity losses 
measurement
Ruff et al. (21) Germany Tobacco Direct costs/indirect costs Prevalence-based Human capital method
Garcia-Altes et al. (27) Spain Illicit drugs Direct costs/indirect costs Prevalence-based Human capital method
Varney and Guest (26) Scotland Alcohol Direct costs/indirect costs Prevalence-based Human capital method
Fenoglio et al. (25) France Alcohol, tobacco, and illicit drugs Direct costs/indirect costs Prevalence-based Human capital method
Rasmussen et al. (24) Denmark Tobacco Direct costs/indirect costs Incidence-based Human capital method
Neubauer et al. (20) Germany Tobacco Direct costs/indirect costs Prevalence-based Human capital method
Konnopka and König (18) Germany Alcohol Direct costs/indirect costs Prevalence-based Human capital method
Rehm et al. (23) Canada Alcohol, tobacco, and illicit drugs Direct costs/indirect costs Prevalence-based Human capital method
Jarl et al. (28) Sweden Alcohol Direct costs/indirect costs/intangible 
costs
Prevalence-based Human capital method
Konnopka et al. (33) Germany Alcohol Direct costs/indirect costs/intangible 
costs
Prevalence-based Human capital method
Hansen et al. (29) US Psychoactive pharmaceuticals Direct costs/indirect costs Prevalence-based Human capital method
Wacker et al. (22) Germany Tobacco Direct costs/indirect costs Prevalence-based Human capital method
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productivity losses measurement (human capital, demographic, 
or friction cost measurement), cost items considered, and a 
number of reporting issues. Study quality was assessed using a 
checklist for social cost studies (Table A1 in Appendix) (17).
ReSULTS
The literature review encompassed 12 studies. Five of them were 
conducted in Germany (18–22), while the remaining were from 
Canada (23), Denmark (24), France (25), Scotland (26), Spain 
(27), Sweden (28), and the US (29). In two studies (23, 25), the 
social costs of alcohol, tobacco, and illicit drugs were estimated, 
while in the other studies, the economic impact of one particu-
lar substance was considered (Table  1). A prevalence-based 
approach was used in 11 of 12 studies (Table 1). In all studies, 
both the indirect and the direct cost categories were accounted 
for, while in only two studies (19, 28), also welfare losses were 
considered. In Jarl et al. (28), quality of life of alcohol consumers, 
their family, and friends was taken into account by calculating 
the number of quality-adjusted life years (QALYs) for the con-
sumers and a weighted quality of life estimate for the relatives. 
In Konnopka and König (19), also QALYs were used to express 
the impact of alcohol on quality of life of individuals consuming 
moderate alcohol levels. In both studies in the base case analysis, 
no monetary valuation of the alcohol-attributable welfare losses 
was included. The human capital approach was used in all stud-
ies to estimate the indirect costs associated with substance use 
(Table 1).
Information on the total costs as a proportion of the gross 
domestic product (GDP) was provided in four studies (Table 2). 
The quantification of the amount of morbidity and mortality that 
could be attributed to legal or illegal drugs occurred in seven stud-
ies by applying the concept of SAFs (Table 2). In all seven studies, 
information on the input parameters to calculate the SAFs was 
provided. In the study by Ruff et  al. (21), attributable risks for 
tobacco-associated diseases were applied, but no information 
on the data source was provided. In Garcia-Altes et al. (27), the 
estimation of the attributable risks was based on the findings from 
previous studies and on Spanish statistical data. Sensitivity analy-
ses were conducted in eight studies (Table 2). In general, three 
categories of sensitivity analyses could be distinguished (Table 3). 
A first category was related to the use of alternative methodologi-
cal approaches. In five studies (18, 20, 22, 23, 28), this consisted 
of applying the friction cost method as an alternative method to 
estimate the substance-attributable indirect costs. In one study 
(28), as a sensitivity analysis, the welfare losses—expressed as 
QALYs—were valued. A second category included sensitivity 
analyses related to the inclusion or exclusion of certain cost 
items (Table 3). In a third category of sensitivity analyses, input 
parameters such as the relative risks of the substance-attributable 
diseases or resource use were varied (Table 3).
In 11 of 12 studies, the major cost categories “direct costs” and 
“indirect costs” were reported in a disaggregated form (Table 2). 
This means that, for each cost item, detailed information on the 
costs was provided. Contrary, in the study by Rasmussen et al. 
(24), only the total direct and indirect tobacco-attributable costs 
were reported. For the direct costs, substance-attributable hos-
pitalization costs were included in all studies, followed by phar-
maceuticals (n = 11), and primary care costs (n = 9). Contrary, 
a number of cost items such as accident and emergency care, 
laboratory tests, home-based nursing care, and household care 
were accounted for in only a limited number of studies (Table 4). 
An important reason for not considering certain cost items was 
the absence of accurate and reliable data. For the indirect costs, 
disability/absenteeism and premature mortality were accounted 
for in 11 studies each, while substance-attributable costs related 
to unemployment were included in only two studies (Table 4).
As an example to illustrate how differences in cost items 
included may have affected the cost outcomes, we focus on the 
five studies conducted in Germany (18–22). For these studies, 
a more in-depth analysis of differences in cost items considered 
was performed. Certain cost items such as hospitalization, reha-
bilitation, and medication use were included in all five studies. 
Others were only considered in one particular study such as 
substance-attributable costs for home-based nursing care (21), 
household care (19), or non-medical costs (18) (Table 4). For the 
indirect costs, expenditures associated with disability, premature 
mortality, and early retirement were accounted for in four of five 
studies (18–21). In the study by Wacker et al. (22), only indirect 
costs due to disability were included in the analysis.
TABLe 3 | Applied sensitivity analyses in the studies included in the 
review.
Category Type Reference
Methodological 
approaches
Friction cost method Wacker et al. (22), Jarl et al. (28), 
Konnopka and König (18), Rehm 
et al. (23), and Neubauer et al. (20)
Valuation of QALYs Jarl et al. (28)
Cost items Exclusion of unpaid 
work
Konnopka et al. (33), Konnopka and 
König (18)
Inclusion of unpaid 
work
Neubauer et al. (20)
Input parameters Resource use Wacker et al. (22), Jarl et al. (28), and 
Varney and Guest (26)
Relative risks Konnopka et al. (33) and Rasmussen 
et al. (24)
Substance 
consumption rates
Konnopka et al. (33)
Discount rates Konnopka et al. (33), Konnopka and 
König (18), and Rasmussen et al. (24)
QALYs, quality-adjusted life years.
TABLe 2 | Reporting issues of the studies included in the review.
Reference Substance Details on cost items Sensitivity analyses % of gDP SAF
Ruff et al. (21) Tobacco Disaggregated No No Not clear
Garcia-Altes et al. (27) Illicit drugs Disaggregated No Yes No
Varney and Guest (26) Alcohol Disaggregated Yes No No
Fenoglio et al. (25) Alcohol/tobacco/illicit drugs Disaggregated No Yes Yes
Rasmussen et al. (24) Tobacco Aggregated Yes No Yes
Neubauer et al. (20) Tobacco Disaggregated Yes No Yes
Konnopka and König (18) Alcohol Disaggregated Yes Yes Yes
Rehm et al. (23) Alcohol/tobacco/illicit drugs Disaggregated Yes No Yes
Jarl et al. (28) Alcohol Disaggregated Yes Yes Yes
Konnopka et al. (33) Alcohol Disaggregated Yes No Yes
Hansen et al. (29) Psychoactive pharmaceuticals Disaggregated No No No
Wacker et al. (22) Tobacco Disaggregated Yes No No
SAF, substance-attributable fraction; GDP, gross domestic product.
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DiSCUSSiON
The aim of the current literature review was to evaluate the 
methodological approaches and considerations in studies exam-
ining the economic impact of alcohol, tobacco, illicit drugs, and 
psychoactive pharmaceuticals. In 11 of 12 studies included in the 
review, the prevalence-based approach was used. The choice for 
a prevalence-based or an incidence-based method is depending 
on the aim of the study. A prevalence-based approach is more 
appropriate for estimating the economic burden of a substance in 
a specified time period. The incidence-based approach portrays 
the magnitude of the economic impact during an individuals’ 
life course, thus providing insights into the value of preventing a 
case of substance use (8). In all studies, the major cost categories 
such as direct costs and indirect costs were included, while the 
intangible costs were accounted for in only two studies. The 
latter costs are often ignored in social cost studies of substance 
misuse since it is difficult to place a monetary value upon welfare 
losses (30). Considerable differences were found related to the 
cost items included or excluded across the studies in the review. 
Our findings are similar with those of a previous literature review, 
however, limited to social cost studies examining the economic 
burden of alcohol. Differences in methodologies related to the 
availability and accuracy of data were found to be important rea-
sons explaining the differences in cost estimates (31). Our review 
was extended to all addictive substances. We found not only dif-
ferences in method but also differences in the drug under study, 
with only limited studies examining more than one substance. 
It is clear that methodological inconsistencies have important 
effects putting the reliability of cost-of-illness findings into ques-
tion. This may result in an underestimation or overestimation of 
the real economic burden of substance misuse to society (32). 
This is a critical element since the findings of such studies may 
serve as the basis for comparative health economic evaluations 
or for policy decisions (8). Methodological considerations are 
not limited to cost-of-illness studies of substance use, but they 
were also found in several literature reviews of the economic 
impact of mental disorders (33–35). For example, in their review, 
Luppa et al. (34) found that costs of morbidity and mortality were 
included in only half and in one-third of studies examining the 
social costs of depression.
It is thus clear that comparing the findings of social cost 
studies is difficult. A possible basis for comparing the findings 
across studies is presenting them relative to a country’s GDP. 
This occurred in four studies included in the current review. 
Nevertheless, even if a uniform methodology was to be devel-
oped and used, cross-country comparisons would necessitate 
sufficient contextualization since countries differ in terms of 
social security systems, institutional structures, and cultural 
traditions (36). In 11 of 12 studies included in the review, 
information on the relative proportion of the different cost 
items to the total costs was provided. This is important because 
different stakeholders may be interested in different outcomes. 
For governments, the findings can assist them in their decisions 
related to the funding of interventions designed to reduce the 
burden of substance misuse. Information regarding the impact 
of substance misuse on productivity can be useful for employers, 
while for households, the impact on medical or other expenses 
can be relevant (15, 16). Sensitivity analyses were applied in eight 
studies included in the review. Uncertainty around certain cost 
estimates in cost-of-illness studies is almost self-evident. It is, 
however, necessary to address this and inform the reader about 
TABLe 4 | Cost items pertaining to the major cost categories included in the social cost studies.
Cost items Ruff 
et al. 
(21)
garcia-
Altes 
et al. 
(27)
varney 
and 
guest 
(26)
Fenoglio 
et al. (25)
Rasmussen 
et al. (24)
Neubauer 
et al. (20)
Konnopka 
and König 
(18)
Rehm 
et al. 
(23)
Jarl 
et al. 
(28)
Konnopka 
et al. (33)
Hansen 
et al. 
(29)
wacker 
et al. 
(22)
Direct costs
Hospitalization x x x x x x x x x x x x
A&E x x
Ambulatory care x x x x x x x x
Ambulance x x x
Residential care x x x
Rehabilitation x x x x x
Pharmaceuticals x x x x x x x x x x x
Primary care x x x x x x x x x
Laboratory tests x
Home-based nursing care x x
Social services x x
Household care x
Non-medical costs x
Education x x
Prevention x x x x x x
Research x x x x x
indirect costs
Disability/absenteeism x x x x x x x x x x x
Unemployment x x
Premature mortality x x x x x x x x x x x
Early retirement x x x x x x
intangible costs
QALY x x
A&E, Accident and Emergency Department; QALY, quality-adjusted life year.
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the amount of uncertainty associated with the cost estimate 
outcomes (10).
Some limitations of our review need to be addressed. First, 
no robust analysis of the magnitude of the economic impact in 
monetary terms was performed, since we focused on methodo-
logical issues of social cost studies of substance use. Nevertheless, 
as an example, the influence of methodological choices on the 
cost outcomes for the German studies was examined. Second, in 
a number of studies (25–29), also drug-attributable crime and 
law enforcement costs were estimated. For the current review, 
methodological considerations related to the estimation of these 
costs were not considered. It is yet important to not omit these 
costs in studies examining the economic impact of substance 
use, since they may account for a considerable part of the total 
costs (23, 37, 38). For example, in the study by Rehm et al. (23) 
examining the social costs of alcohol, tobacco, and illicit drugs, 
the costs for law enforcement constituted more than one-third of 
the direct costs. Third, only studies published after the introduc-
tion of the guidelines for estimating the costs of substance abuse 
in 1996 were eligible for inclusion in the review. It is thus possible 
that we missed some relevant studies prior to 1997. Fourth, we 
did not search the gray literature. It is thus possible that we have 
missed social cost studies of addictive substances not published 
in peer-reviewed journals. Fifth, the current review was limited to 
social cost studies conducted in high-income countries. However, 
the economic burden attributable to the addictive substances 
alcohol, tobacco, and illicit drugs is also considerable in low- 
and middle-income countries (39). So, it is clear that addictive 
substances pose a considerable economic impact to societies 
worldwide. In conclusion, the current review has illustrated the 
complexity of dealing with all consequences of substance use in 
cost-of-illness studies. Future social cost studies should be based 
on sound methodological principles in order to result in more 
reliable cost estimates of the economic burden of substance use. 
This is important since the findings of such studies may be used 
as the basis for comparative health economic evaluations and for 
substance use policies.
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TABLe A1 | Quality appraisal of studies included in the literature review.
Quality check item Ruff 
(21)
garcia-Altes 
et al. (27)
varney and 
guest (26)
Fenoglio 
et al. (25)
Rasmussen 
et al. (24)
Neubauer 
et al. (20)
Konnopk 
and König 
(18)
Rehm 
et al. 
(23)
Jarl 
et al. 
(28)
Konnopka 
et al. (33)
Hansen 
et al. (29)
wacker 
et al. 
(22)
Clear definition of the illness? x x x x x x x x x x x x
Epidemiological sources carefully described? x x x x x x x x x x x x
Costs sufficiently disaggregated? x x x x x x x x x x x
Activity data sources carefully described? x x x x x x x x x x x x
Activity data appropriately assessed? x x x x
Sources of all cost values analytically described? x x x x x x x x x x x
Methods carefully explained? x x x x x x x x x
Costs discounted? x x x x x x x
Major assumptions tested in a sensitivity analysis? x x x x x x x x
Presentation of results consistent with methodology? x x x x x x x x x x x x
